Sanuwave Announces Q1 FY2025 Financial ResultsQ1 2025 revenues were $9.3 million, up 61% from $5.8 million in Q1 2024. This represents the highest Q1 quarterly revenues in Company history.
Sanuwave Will Host a Conference Call on May 9, 2025 at 8:30 AM (ET) to Present Q1 2025 Financial ResultsEDEN PRAIRIE, Minn., May 05, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (
NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, May 9, 2025, at 8:30 AM (ET) to present its Q1 2025 financial results.
SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025)SANUWAVE is pleased to announce preliminary revenues of $9.1 million to $9.3 million for the first quarter ended March 31, 2025. This represents the highest Q1 quarterly revenues in Company history.
SANUWAVE Announces Record Quarterly Revenues: Q4 FY2024 Financial ResultsQ4 2024 revenues were $10.3 million, up 47% from Q4 2023. This was an all-time quarterly record for the Company.
SANUWAVE Will Host a Conference Call on March 21, 2025 at 8:30 AM (ET) to Present Q4 and Full Year 2024 Financial Results
SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (
NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, March 21, 2025, at 8:30 AM (ET) to present its Q4 and Full Year 2024 financial results.
